The production of reactive oxygen intermediates (ROI) and reactive nitrogen intermediates (RNI) is an important host defense mechanism in response to infection by Mycobacterium tuberculosis. A variety of genes have been implicated in resistance to ROI and RNI, including noxR1. However, studies in Mycobacterium avium, an important pathogen among nontuberculous mycobacteria, are limited. We aim to investigate the role of a novel gene cloned from M. avium with high similarity to noxR1, noA, in resistance against RNI and ROI in M. tuberculosis. After subcloning noA into vector for expression in E. coli, we performed survival rate analysis in the bacteria transformed with noA (pET-noA) and without noA (pET-his) after exposure to nitrosative stresses by S-nitrosoglutathione (GSNO) and sodium nitrite, and oxidative stresses by HO. Compared with pET-his, the survival rate of pET-noA was 1 log-fold higher after exposure to GSNO and sodium nitrite. We observed 1 log-fold, 2 log-fold and 3 log-fold higher survival rate in pET-noA than pET-his after exposure to HO for 3, 6 and 9 h, respectively. With the combined treatment of HO and GSNO, we found more than 2 log-fold increase in survival rate in pET-noA comparing with pET-his, suggesting a possible synergistic effect. In summary, noA gene cloned from M. avium has been shown to protect E. coli from both RNI and ROI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11274-017-2294-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Promising Druggable Target for Translational Therapy of Ovarian Cancer: A Molecular Profiling of Therapeutic Innovations, Extracellular Vesicle Acquired Resistance, and Signaling Pathways.
Curr Med Chem
January 2025
Department of Biochemistry, J.N. Medical College, Faculty of Medicine, Aligarh Muslim University, Aligarh, India.
Ovarian cancer (OC) ranks as the fifth leading cause of cancer-related deaths in the United States, posing a significant threat to female health. Late-stage diagnoses, driven by elusive symptoms often masquerading as gastrointestinal issues, contribute to a concerning 70% of cases being identified in advanced stages. While early-stage OC brags a 90% cure rate, progression involving pelvic organs or extending beyond the peritoneal cavity drastically diminishes it.
View Article and Find Full Text PDFPersonalized Nanovaccine Based on STING-Activating Nanocarrier for Robust Cancer Immunotherapy.
ACS Nano
January 2025
Medical Research Center, The First Affiliated Hospital of Zhengzhou University, The Center of Infection and Immunity, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, China.
Tumor-specific T cells play a vital role in potent antitumor immunity. However, their efficacy is severely affected by the spatiotemporal orchestration of antigen-presentation as well as the innate immune response in dendritic cells (DCs). Herein, we develop a minimalist nanovaccine that exploits a dual immunofunctional polymeric nanoplatform (DIPNP) to encapsulate ovalbumin (OVA) via electrostatic interaction when the nanocarrier serves as both STING agonist and immune adjuvant in DCs.
View Article and Find Full Text PDFDysregulation of genes involved in the long-chain fatty acid transport in pancreatic ductal adenocarcinoma.
World J Gastrointest Oncol
January 2025
Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest 050474, Romania.
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive lethal malignancy with limited options for treatment and a 5-year survival rate of 11% in the United States. As for other types of tumors, such as colorectal cancer, aberrant lipid synthesis and reprogrammed lipid metabolism have been suggested to be associated with PDAC development and progression.
Aim: To identify the possible involvement of lipid metabolism in PDAC by analyzing in tumoral and non-tumoral tissues the expression level of the most relevant genes involved in the long-chain fatty acid (FA) import into cell.
Transarterial chemoembolization combined with lenvatinib and sintilimab lenvatinib alone in intermediate-advanced hepatocellular carcinoma.
World J Gastrointest Oncol
January 2025
Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
Background: Hepatocellular carcinoma (HCC) is the most common form of liver cancer that has limited treatment options and a poor prognosis. Transarterial chemoembolization (TACE) is the first-line treatment for intermediate-stage HCC but can induce tumour hypoxia, thereby promoting angiogenesis. Recent studies suggested that combining TACE with anti-angiogenic therapies and immunotherapy might improve efficacy.
View Article and Find Full Text PDFPopulation-Based Analysis of Late Outcomes of Mitral Valve Repair for Degenerative Mitral Valve Regurgitation.
JACC Adv
December 2024
Department of Cardiovascular Surgery, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Background: Population-based analyses may reduce uncertainty related to referral bias and/or incomplete follow-up.
Objectives: This study analyzed long-term mortality and durability of mitral valve repair in a geographically defined population with clinical and echocardiographic follow-up.
Methods: We used the Rochester Epidemiology Project to identify 153 Olmsted County patients who underwent mitral valve repair for degenerative regurgitation from 1993 to 2018.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!